Maher M. Haddad

Array ( [id] => 17838947 [patent_doc_number] => 20220276252 [patent_country] => US [patent_kind] => A9 [patent_issue_date] => 2022-09-01 [patent_title] => ANTIBODIES SPECIFIC TO GLYCOSYLATED PD-L1 AND METHODS OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 17/097817 [patent_app_country] => US [patent_app_date] => 2020-11-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 41630 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17097817 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17838947 [patent_doc_number] => 20220276252 [patent_country] => US [patent_kind] => A9 [patent_issue_date] => 2022-09-01 [patent_title] => ANTIBODIES SPECIFIC TO GLYCOSYLATED PD-L1 AND METHODS OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 17/097817 [patent_app_country] => US [patent_app_date] => 2020-11-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 41630 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17097817 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18093182 [patent_doc_number] => 20220411523 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-12-29 [patent_title] => MOLECULE CAPABLE OF BINDING TO HUMAN 4-1BB AND ITS APPLICATION THEREOF [patent_app_type] => utility [patent_app_number] => 17/774972 [patent_app_country] => US [patent_app_date] => 2020-11-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19585 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17774972 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18451539 [patent_doc_number] => 20230192817 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-06-22 [patent_title] => Anti-Varicella-Zoster Virus Antibody [patent_app_type] => utility [patent_app_number] => 17/775727 [patent_app_country] => US [patent_app_date] => 2020-11-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9840 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 148 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17775727 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18341903 [patent_doc_number] => 11639377 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-05-02 [patent_title] => Preparation of type I collagen-like fiber and method for regulating and controlling the D-periodic of fiber thereof [patent_app_type] => utility [patent_app_number] => 17/082525 [patent_app_country] => US [patent_app_date] => 2020-10-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 15 [patent_figures_cnt] => 20 [patent_no_of_words] => 5004 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 111 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17082525 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16824280 [patent_doc_number] => 20210139573 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-05-13 [patent_title] => DOSING REGIMENS FOR TREATING OR PREVENTING C5-ASSOCIATED DISEASES [patent_app_type] => utility [patent_app_number] => 17/078309 [patent_app_country] => US [patent_app_date] => 2020-10-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 40050 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -27 [patent_words_short_claim] => 64 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17078309 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18362954 [patent_doc_number] => 20230144545 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-05-11 [patent_title] => PROPHYLACTIC AND/OR THERAPEUTIC AGENT FOR INFLAMMATORY PULMONARY DISEASE [patent_app_type] => utility [patent_app_number] => 17/768865 [patent_app_country] => US [patent_app_date] => 2020-10-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10729 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -24 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17768865 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18428732 [patent_doc_number] => 11673942 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-06-13 [patent_title] => Fusion proteins for ophthalmology with increased eye retention [patent_app_type] => utility [patent_app_number] => 17/066215 [patent_app_country] => US [patent_app_date] => 2020-10-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 18684 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 83 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17066215 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18428746 [patent_doc_number] => 11673956 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-06-13 [patent_title] => Anti-galectin-1 (Gal1) monoclonal antibodies and fragments thereof for neutralizing Gal1 [patent_app_type] => utility [patent_app_number] => 17/065151 [patent_app_country] => US [patent_app_date] => 2020-10-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 7 [patent_no_of_words] => 33961 [patent_no_of_claims] => 4 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 68 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17065151 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18575539 [patent_doc_number] => 11732053 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-08-22 [patent_title] => Methods of treatment by targeting VCAM1 and MAEA [patent_app_type] => utility [patent_app_number] => 17/061219 [patent_app_country] => US [patent_app_date] => 2020-10-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 114 [patent_figures_cnt] => 221 [patent_no_of_words] => 25908 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 106 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17061219 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19226730 [patent_doc_number] => 12006363 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-06-11 [patent_title] => Anti-tetraspanin 33 agents and compositions and methods for making and using the same [patent_app_type] => utility [patent_app_number] => 17/028202 [patent_app_country] => US [patent_app_date] => 2020-09-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 15 [patent_figures_cnt] => 15 [patent_no_of_words] => 40681 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 209 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17028202 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16749956 [patent_doc_number] => 20210101965 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-04-08 [patent_title] => COMPLEMENT COMPONENT C5 ANTIBODIES [patent_app_type] => utility [patent_app_number] => 17/001604 [patent_app_country] => US [patent_app_date] => 2020-08-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 31972 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 184 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17001604 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18077436 [patent_doc_number] => 20220403048 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-12-22 [patent_title] => BINDING MOLECULES TO ARGINASE II [ARG2] [patent_app_type] => utility [patent_app_number] => 17/637052 [patent_app_country] => US [patent_app_date] => 2020-08-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 39520 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17637052 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16711929 [patent_doc_number] => 20210079076 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-03-18 [patent_title] => Use of Antibody [patent_app_type] => utility [patent_app_number] => 16/997306 [patent_app_country] => US [patent_app_date] => 2020-08-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10381 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16997306 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18302071 [patent_doc_number] => 11623962 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-04-11 [patent_title] => Anti-OX40 binding proteins [patent_app_type] => utility [patent_app_number] => 16/995573 [patent_app_country] => US [patent_app_date] => 2020-08-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 7 [patent_no_of_words] => 34876 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 66 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16995573 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20414176 [patent_doc_number] => 12497446 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-12-16 [patent_title] => Tetranectin-targeting monoclonal antibodies to fight against lethal sepsis and other pathologies [patent_app_type] => utility [patent_app_number] => 17/634430 [patent_app_country] => US [patent_app_date] => 2020-08-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 22 [patent_figures_cnt] => 22 [patent_no_of_words] => 16669 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 124 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17634430 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17428419 [patent_doc_number] => 20220056127 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-02-24 [patent_title] => TREATMENT OF EOSINOPHIL OR MAST CELL RELATED DISORDERS [patent_app_type] => utility [patent_app_number] => 16/984829 [patent_app_country] => US [patent_app_date] => 2020-08-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 45563 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -44 [patent_words_short_claim] => 44 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16984829 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16598105 [patent_doc_number] => 20210024636 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-01-28 [patent_title] => COMPOSITIONS AND METHODS FOR TREATING SEXUAL DYSFUNCTION [patent_app_type] => utility [patent_app_number] => 16/939657 [patent_app_country] => US [patent_app_date] => 2020-07-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5332 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 23 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16939657 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16598406 [patent_doc_number] => 20210024937 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-01-28 [patent_title] => Methods of Modulating Lymphangiogenesis, E.g., to Treat Corneal Transplant Rejection, in a Subject [patent_app_type] => utility [patent_app_number] => 16/933263 [patent_app_country] => US [patent_app_date] => 2020-07-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 25959 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 37 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16933263 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18020640 [patent_doc_number] => 20220372139 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-11-24 [patent_title] => ANTI-TREM-1 ANTIBODIES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/627070 [patent_app_country] => US [patent_app_date] => 2020-07-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 40128 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 153 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17627070 [rel_patent_id] =>[rel_patent_doc_number] =>)